Article
Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib.
Scientific reports - 20 Sept 2017
Novo Sonia M, Wedge Stephen R, Stark Lesley A
Abstract excerpt
Although an array of new therapeutics has emerged for the treatment of colorectal cancer, their use is significantly impacted by variability in patient response. Better pre-clinical models could substantially improve efficacy as it may allow stratification of patients into the correct treatment regime. Here we explore acute, ex vivo treatment of fresh, surgically resected human colorectal tumour biopsies as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.